Nearly 319,000 older Americans are admitted to hospital with a broken hip every year, the Centers for Disease Control and Prevention (CDC) reports, and the world logged about 178 million new fractures in 2019 on the Global Burden of Disease count. Those broken bones fund the orthopedic trauma implants market, which Douglas Insights sizes at USD 10.40 billion in 2025, rising to USD 16.85 billion in 2035 at a 4.95% revenue CAGR. The arithmetic is simple: 13.4 million fixation procedures multiplied by USD 776 of implant spend per procedure gives USD 10.40 billion. Ownership of the biggest supplier is about to change: on 14 October 2025 Johnson & Johnson announced it would separate its orthopaedics business as a standalone DePuy Synthes within 18 to 24 months. The study belongs to our orthopaedic devices coverage and is built under the published research methodology.
Which fracture fixation devices belong in the orthopedic trauma implant count?
Orthopedic trauma implants are the plates, screws, nails and frames that hold 13.4 million broken bones a year while they heal. The market covers those 2025 fixation procedures, worth USD 10.40 billion at manufacturer realised prices. Joint replacement for fracture, spinal fixation and craniomaxillofacial plates sit outside the count.
Five product groups are counted: plates and screws, intramedullary nails driven down the femur, tibia or humerus, hip fracture systems such as sliding hip screws and cephalomedullary nails, external fixators, and bioabsorbable polymers or magnesium screws.
Five fracture sites are tracked: hip and femur, wrist and forearm, ankle and tibia, shoulder and upper arm, and pelvis and other sites. Three materials are tracked: Titanium alloy, stainless steel and bioabsorbable polymers. Douglas Insights estimates that titanium carries about 62% of plate and nail units outside China, because it is lighter, images better and suits locking designs. Care settings are hospitals and ambulatory surgery centers.
Which implant category makes the money in fracture fixation?
Plates and screws make the most money, with 41.7% of 2025 orthopedic trauma implant value, or USD 4.34 billion, because almost every fracture site uses them. Intramedullary nails follow at 24.6%. Bioabsorbable and other fixation grows fastest, at 7.9% a year to 2035.
| Category | Share 2025 | Value 2025 | Growth 2026-2035 | Value 2035 |
|---|---|---|---|---|
| Plates and screws | 41.7% | USD 4.34 billion | 4.6% | USD 6.80 billion |
| Intramedullary nails | 24.6% | USD 2.56 billion | 5.2% | USD 4.25 billion |
| Hip fracture systems | 19.3% | USD 2.01 billion | 5.6% | USD 3.46 billion |
| External fixators | 8.9% | USD 926 million | 2.9% | USD 1.23 billion |
| Bioabsorbable and other fixation | 5.5% | USD 572 million | 7.9% | USD 1.22 billion |
Plates and screws hold USD 4.34 billion because wrist, ankle and clavicle fractures are fixed almost entirely with plates. Intramedullary nails earn USD 2.56 billion: one femoral nail costs several times a small-fragment plate. Hip fracture systems take USD 2.01 billion and grow 5.6% a year, because each extra faller over 80 adds a cephalomedullary nail.
External fixators bring in USD 926 million but grow only 2.9%, since surgeons now convert open injuries to internal fixation sooner. Bioabsorbable and other fixation grows fastest because resorbable polymer and magnesium screws remove the second operation to take hardware out.
Where do trauma implant procedures and revenue concentrate by region?
North America leads with 40.6% of 2025 orthopedic trauma implant revenue, USD 4.22 billion, because US hospitals pay several times the world average per implant. Asia Pacific grows fastest at 6.7% a year to 2035, as surgical fixation spreads across India and Southeast Asia.
North America grows 4.2% a year to USD 6.37 billion, helped by premium titanium locking systems. Europe holds 24.8%, USD 2.58 billion, and grows 3.8%, the slowest rate, because diagnosis-related group (DRG) payments cap spend per hip. Asia Pacific holds 25.9%, USD 2.69 billion, and reaches USD 5.15 billion by 2035, though China’s procedures earn little after tender cuts.
Latin America contributes USD 510 million and grows 5.8% a year, led by Brazil’s road-trauma caseload. The Middle East and Africa is the wildcard at USD 395 million, growing 5.74% a year on Gulf hospital building.
How many fragility fractures reach the orthopedic operating table each year?
About 3.12 million hip and femur fixation procedures took place in 2025 on Douglas Insights’ count, the largest share of the trauma implant workload by value. Most follow a fall from standing height in a patient over 75 whose osteoporosis has thinned the femoral neck.
The CDC attributes 88% of hip fracture emergency visits and hospital stays to falls, and more than one in four Americans aged 65 or over falls each year. Hip fracture surgery is close to universal in rich countries. A study of 4,115,046 hip fractures across 19 countries and regions, published through the University of Oxford, projects that the annual number of hip fractures roughly doubles between 2018 and 2050.
Lower-leg and ankle breaks are the most common fracture worldwide, at an age-standardised 419.9 per 100,000 people in the Global Burden of Disease series. Douglas Insights estimates that only about 7.0% of the world’s roughly 190 million annual fractures receive an implant; the rest are casted, splinted or left untreated.
Why are orthopedic trauma implant volumes climbing 3.6% a year?
Orthopedic trauma implant procedures are growing 3.6% a year to 2035, from 13.4 million to 19.1 million. Ageing populations contribute 1.9 points, wider surgical access 1.0 point, road and high-energy trauma 0.4 point and new fixation technology 0.3 point of that yearly gain.
Fragility fractures rise steeply with age; a person over 85 is many times likelier to break a hip than one aged 65. The population aged 80 and over is the fastest-growing age band in Japan, Western Europe, China and North America. Douglas Insights counts hip and femur procedures rising from 3.12 million in 2025 to about 4.9 million by 2035, which accounts for most of the increase in cephalomedullary nail demand. Weaker bone also changes what surgeons buy: locking plates and augmented screws that hold in osteoporotic bone cost more than standard implants.
Surgical access adds 1.0 point. In India, Indonesia, Vietnam, Nigeria and much of Latin America, many long-bone fractures are still managed with traction or a cast because there is no operating room, implant or trained surgeon available. Every new district hospital with an image intensifier moves cases from casting to plating. Low-cost implants of about USD 85 to USD 180 per system, made by Chinese and Indian producers, are what make that shift affordable. Douglas Insights expects the surgically treated share of fractures in lower-middle-income countries to rise from about 3.1% to 4.6% over the decade.
Road and high-energy trauma adds 0.4 point. Motorcycle crashes in South and Southeast Asia produce femur, tibia and pelvis fractures in young adults, and each case uses an intramedullary nail or a pelvic plate set. Wealthy countries are moving the other way as vehicle safety improves, so this driver is concentrated in Asia, Africa and Latin America.
Technology adds 0.3 point. Anatomically contoured plates, variable-angle locking screws, navigation and robotic guidance for pelvic and sacral screws, covered in our Surgical Robotics Market report, make surgery possible for fractures that were once treated without it. Zimmer Biomet completed its acquisition of Paragon 28 on 21 April 2025, paying USD 13.00 a share plus a contingent right, to add foot and ankle fixation.
How deep did China’s volume-based procurement cut trauma plate and nail prices?
China’s volume-based procurement cut trauma implant prices by an average of 88.65% in the Henan-led 12-province alliance, which covered 147 representative products. Locking plate systems fell about 89%, from roughly 9,360 yuan to 987 yuan, which permanently reset orthopedic trauma implant revenue per Chinese case.
Under volume-based procurement (VBP), provincial alliances award guaranteed hospital volumes to the lowest compliant bids. In the 12-province round, 71 of 89 bidding firms won contracts, and more than 85% of bidders were domestic. A standard plate system dropped from about 4,683 yuan to 606 yuan, a cut of 87.05%. An intramedullary nail system fell from about 11,687 yuan to 1,271 yuan, a cut of 89.12%. Later rounds, including the Beijing-Tianjin-Hebei “3+N” alliance of 17 members, used the Henan winning prices as ceilings, so the cuts spread nationwide.
In dollars, a Chinese locking plate system now realises about USD 137 and a nail system about USD 177. Douglas Insights puts China at about 2.3 million fixation procedures but only about USD 610 million of 2025 revenue, with Weigao Orthopaedics and Double Medical taking most of the volume.
Which headwinds hold orthopedic trauma implant revenue below procedure growth?
Three headwinds remove 1.6 points a year from orthopedic trauma implant pricing: procurement tenders take 0.9 point, fixed per-case hospital payments 0.4 point and commoditised standard screws 0.3 point. A richer mix of products adds 2.9 points, which leaves the 1.3% net price leg.
Procurement removes 0.9 point. China’s VBP ceilings are being copied for products not yet tendered, and Middle Eastern national buyers tender annually. New rounds tend to land 50% to 90% below the previous list price for standard plates.
Fixed hospital payments remove 0.4 point. US Medicare pays hospitals a single amount for each hip fracture stay, and European DRG tariffs work the same way, so an implant price increase comes straight out of the hospital’s margin. Value-analysis committees now standardise trauma sets around one or two suppliers, trading volume for discounts that our tender file puts at 10% to 20%.
Commoditisation removes 0.3 point. Cannulated screws, K-wires and small-fragment plates are off patent and sold by dozens of suppliers. Douglas Insights estimates that standard-design products make up about 46% of trauma implant units but only about 21% of value, and that share of units edges up each year.
Can fracture liaison services and osteoporosis drugs dent orthopedic trauma implant volumes?
Fracture prevention takes only about 0.2 point a year off orthopedic trauma implant volume growth in the Douglas Insights model. Treatment after a first fracture remains patchy: one-year anti-osteoporosis drug use ranges from 11.5% in Germany to 50.3% in the United Kingdom.
Those figures come from the same 19-country hip fracture study published through Oxford, which also recorded one-year mortality of 14.4% in Singapore and 28.3% in the United Kingdom. Fracture liaison services find patients after their first fragility fracture and start bone-protection therapy, since a first break sharply raises the risk of the next. Fewer than half of eligible patients receive bone-protection drugs.
Two forces outweigh prevention. The population aged 80 and over grows faster than treatment rates rise. Prevention mainly cuts second fractures, while a first hip or wrist fracture still sends the patient to surgery. Douglas Insights therefore lowers incidence per older person by about 1.8% over ten years while total procedures still rise by 5.7 million, from 13.4 million to 19.1 million.
Which companies win orthopedic trauma implant tenders, and how concentrated is supply?
The top three suppliers, DePuy Synthes, Stryker and Zimmer Biomet, hold about 55.5% of 2025 orthopedic trauma implant revenue, on Douglas Insights estimates anchored on their disclosed franchise sales. J&J’s DePuy Synthes leads with about a 30.3% share of revenue.
| Company | Disclosed 2025 line | Douglas Insights trauma estimate | Estimated share | Position built on |
|---|---|---|---|---|
| Johnson & Johnson (DePuy Synthes) | Trauma USD 3.15 billion | USD 3.15 billion | 30.3% | Locking plates, femoral and tibial nails, hospital consignment sets |
| Stryker | Trauma and Extremities USD 3.95 billion | USD 2.06 billion | 19.8% | Gamma hip nails, foot and ankle, US ambulatory surgery centers |
| Zimmer Biomet | S.E.T. USD 2.15 billion | USD 560 million | 5.4% | Plates and nails, Paragon 28 foot and ankle |
| Smith+Nephew | Trauma and Extremities USD 649 million | USD 470 million | 4.5% | Hip nails, external fixation frames |
Johnson & Johnson reported worldwide trauma sales of USD 3.15 billion in fiscal 2025, up from USD 3.05 billion, inside orthopaedics sales of USD 9.26 billion. Stryker’s 2025 Form 10-K shows Trauma and Extremities sales of USD 3.95 billion, up from USD 3.51 billion; we strip out joint replacement to reach its trauma estimate.
Zimmer Biomet’s sports, extremities and trauma category reached USD 2.15 billion in 2025, up 15.2% with Paragon 28 included. Smith+Nephew reported Trauma and Extremities revenue of USD 649 million, up 6.7%. Acumed is strong in upper-extremity plating, Enovis in foot and ankle, and Globus Medical has built a trauma plating line beside its spine business. Arthrex sells small-fragment systems; Weigao Orthopaedics and Double Medical lead China’s tender volume.
What does a locking plate, femoral nail or hip screw cost hospitals?
Orthopedic trauma implant spend averages USD 776 per procedure worldwide in 2025. Realised prices range from about USD 85 for a tendered Chinese plate system to over USD 4,000 for a US femoral nail construct, depending on country, design and setting.
Douglas Insights puts realised US prices at USD 1,400 to USD 3,200 for a distal radius or ankle locking plate construct with screws. A femoral or tibial intramedullary nail with locking screws sells for USD 2,500 to USD 4,200, a sliding hip screw for USD 700 to USD 1,400, and an external fixation frame for USD 1,500 to USD 6,000. Western European prices run about 35% to 50% below US levels under DRG tariffs and national tenders. Chinese VBP prices are 85% to 90% below pre-tender levels.
Most trauma implants reach hospitals on consignment: the supplier keeps loaner sets on site and bills only for implants used. Average spend per procedure rises 1.3% a year to about USD 883 in 2035, because titanium locking and bioabsorbable designs gain share faster than tenders cut prices.
Which device regulations and recall rules govern orthopedic trauma implants?
Orthopedic trauma implants are Class II devices in the United States, cleared through 510(k) under 21 CFR 888.3030. In the European Union most are implantable Class IIb or Class III devices under the Medical Device Regulation, with legacy certificates for that group running to 31 December 2027.
The US route is relatively quick. On 11 August 2025 the FDA cleared Paragon 28’s External Fixation Bone Distractor (K251862) as a Class II, product code KTT device under 21 CFR 888.3030, a typical example of the trauma clearance path. In Europe, Regulation (EU) 2017/745 requires fresh clinical evidence and notified-body review. Regulation (EU) 2023/607 of 15 March 2023 extended transition to 31 December 2027 for implantable Class IIb and Class III devices and 31 December 2028 for others. Several suppliers dropped low-volume plate variants rather than recertify them.
How would the DePuy Synthes separation and procurement reshape the 2035 orthopedic trauma implant forecast?
The base case reaches USD 16.85 billion in 2035 on 3.6% procedure growth and 1.3% price growth. A slower case reaches USD 13.85 billion and a faster case USD 19.69 billion. Procurement spreading beyond China and ageing speed are the two levers.
The slower case, 2.6% volume and 0.3% price, assumes VBP-style tendering spreads to India, Brazil and Gulf buyers. The faster case, 4.4% volume and 2.1% price, assumes quicker surgical access in South Asia and wider uptake of bioabsorbable systems. A single extra point of yearly procedure growth adds about USD 1.70 billion to the 2035 total.
Ownership is the third variable. The DePuy Synthes separation announced on 14 October 2025 creates a standalone company with about USD 9.2 billion of 2024 orthopaedics sales. If it prices trauma for margin rather than share, the price leg moves toward the faster case; if it cuts prices to defend share against Stryker, it moves toward the slower case. Published forecasts span roughly 3.5% to 8.5% a year; our 4.95% sits in the lower half because China’s tender pricing is fully reflected.
Who holds the profit in orthopedic trauma implants, from maker to operating room?
The orthopedic trauma implant profit pool sits with makers of premium locking plates, nails and hip systems, not with standard screws. Standard designs are about 46% of units but only about 21% of value, so margin follows design, not volume.
The value chain runs from titanium and steel bar to machining, then to supplier-owned loaner sets that sit on hospital shelves under consignment. The supplier carries the set inventory, sterilisation and field representatives, which is the main barrier to entry alongside EU MDR recertification. Buyer power is high and rising: hospital value-analysis committees, DRG and Medicare per-case payments and national tenders all press on price. Hospitals remain the main end user; in the United States, ambulatory surgery centers take a growing share of ankle, foot and wrist cases, where Stryker and Paragon 28 have built positions.
For a supplier, the three clearest openings in the model are hip and femur fixation (34.6% of value), Asia Pacific (6.7% a year) and bioabsorbable fixation (7.9% a year).
Douglas Exclusive: the fracture-site procedure atlas
The fracture-site procedure atlas is a Douglas Insights model, not an official register. It is built from 186 inputs: 38 national fracture incidence series, five site-level surgical treatment rates per region, implant mix by site, and the company filings and tender results cited above. It allocates every orthopedic trauma implant procedure to a fracture site.
| Fracture site | Procedures 2025 | Share of procedures | Share of value | Spend per procedure |
|---|---|---|---|---|
| Hip and femur | 3.12 million | 23.3% | 34.6% | USD 1,153 |
| Wrist and forearm | 3.51 million | 26.2% | 17.8% | USD 527 |
| Ankle and tibia | 3.39 million | 25.3% | 24.1% | USD 739 |
| Shoulder and upper arm | 1.47 million | 11.0% | 11.6% | USD 821 |
| Pelvis and other sites | 1.91 million | 14.3% | 11.9% | USD 648 |
The finding is a mismatch between procedures and value. Wrist and forearm fixation is the most frequent site, with 26.2% of procedures, yet earns only 17.8% of value. Hip and femur work is 23.3% of procedures but 34.6% of value, USD 3.60 billion, because each case uses a nail or a sliding hip screw. Suppliers chasing growth should look at the hip, not the wrist.
How was the orthopedic trauma implant model built, and what methodology checks it?
How this report is built
- Every figure carries a confidence grade in the fact sheet above, and the working model ships with every licence.
- Five regional models sum to the global figure, with country tables in the Excel model.
- The next scheduled review of this study is October 2027.
- Licence holders receive it as a maintained tab in the Excel model.
The orthopedic trauma implant model multiplies 13.4 million fixation procedures by USD 776 of average implant spend to reach USD 10.40 billion for 2025. It covers 38 countries in detail and five regional aggregates, built from 186 inputs and 412 data points.
Procedures start from the Global Burden of Disease count of 178 million fractures in 2019, grown at about 1% a year to roughly 190 million in 2025. Site-level surgical rates of 2% to 95% are then applied. Price comes from tender awards, hospital disclosures and manufacturer franchise revenue. Two cross-checks are used. Summing the disclosed and estimated revenues of the top four suppliers with our estimate for the rest of the field gives USD 10.10 billion, within 2.9% of the bottom-up figure. Our US hip fracture procedure count sits within 4% of the CDC’s 319,000 hospitalisations once femoral shaft cases are added.
How this report was made: AI tools drafted the text and automated checks compared every figure with the model and the cited filings; the research desk chose the sources, built the model and approved the final figures, as set out in our editorial standards. Material inputs such as titanium bar prices are tracked in the Titanium Market report, and 3D-printed porous trauma implants in the Metal Additive Manufacturing Market report.
Sources
- US Centers for Disease Control and Prevention Facts About Older Adult Falls (2025)
- Institute for Health Metrics and Evaluation Global burden of bone fractures, 1990-2019 (2021)
- University of Oxford NDORMS Global epidemiology of hip fractures (2023)
- Johnson & Johnson Johnson & Johnson announces intent to separate its Orthopaedics business (2025)
- Johnson & Johnson Q4 and full-year 2025 results, franchise sales (2026)
- Stryker Corporation (SEC EDGAR) Form 10-K for fiscal 2025 (2026)
- Zimmer Biomet Zimmer Biomet completes acquisition of Paragon 28 (2025)
- Zimmer Biomet Fourth quarter and full-year 2025 financial results (2026)
- Smith+Nephew Fourth quarter and full year 2025 results (2026)
- US Food and Drug Administration 510(k) K251862 External Fixation Bone Distractor (2025)
- EUR-Lex Regulation (EU) 2017/745 on medical devices (2017)
- EUR-Lex Regulation (EU) 2023/607 (2023)
Inside the 180-page report
01Executive summary12 sections
The market in one view
- 1.1Market snapshot, 2025 and 2035
- 1.1.1Market size, 2025
- 1.1.2Forecast, 2035
- 1.1.3Growth rate, 2026–2035
- 1.2Growth decomposition
- 1.2.1Volume growth (million procedures)
- 1.2.2Value per unit growth
- 1.3Key findings
- 1.4Segment highlights
- 1.5Regional highlights
- 1.6Competitive highlights
- 1.7Douglas Insights verdict
02Scope and definitions18 sections
What is counted and what is excluded.
- 2.1Market definition
- 2.2Inclusions and exclusions
- 2.2.1Plates, nails, hip systems, fixators, bioabsorbables
- 2.2.2Titanium, stainless steel, bioabsorbable polymers
- 2.2.3Exclusions: arthroplasty, spine, craniomaxillofacial
- 2.3Segmentation
- 2.3.1By category
- 2.3.2By fracture site
- 2.3.3By material
- 2.3.4By care setting
- 2.3.5By region
- 2.4Years considered
- 2.4.1Base year 2025
- 2.4.2Forecast 2026–2035
- 2.5Currency and units
- 2.5.1Value in USD million
- 2.5.2Volume in million procedures
- 2.6Who this report is for
03Research methodology16 sections
Bottom-up: million procedures × value per unit
- 3.1Bottom-up market model
- 3.1.1Volume base, 2025 (million procedures)
- 3.1.2Value per unit
- 3.1.3Forecast legs to 2035
- 3.2Top-down cross-checks
- 3.3Data triangulation
- 3.4Sources
- 3.4.1Regulators and statistics offices
- 3.4.2Company filings and results
- 3.4.3Trade and industry bodies
- 3.4.412 primary sources cited
- 3.5Confidence grading
- 3.6Assumptions and limitations
- 3.6.1186 inputs, 412 data points
- 3.6.2Top-down revenue cross-check
- 3.6.3Source list
04Implant categories3 sections
Value and growth by category to 2035.
- 4.1Plates and screws
- 4.2Intramedullary nails and hip fracture systems
- 4.3External fixators and bioabsorbable fixation
05Fragility fracture epidemiology3 sections
Hip, wrist and ankle fracture incidence.
- 5.1Falls and hip fractures
- 5.2Global Burden of Disease series
- 5.3Surgical treatment rates
06Volume drivers4 sections
Four drivers and their contributions in points.
- 6.1Ageing
- 6.2Surgical access
- 6.3Road trauma
- 6.4Fixation technology
07China volume-based procurement3 sections
Tender rounds and price resets.
- 7.1Henan-led 12-province alliance
- 7.2Beijing-Tianjin-Hebei 3+N alliance
- 7.3Domestic versus multinational suppliers
08Price headwinds3 sections
Procurement, fixed payments and commoditisation.
- 8.1Tender spread
- 8.2DRG and Medicare payment
- 8.3Standard screws and K-wires
09Fracture prevention3 sections
Fracture liaison services and osteoporosis therapy.
- 9.1Post-fracture treatment rates
- 9.2Mortality after hip fracture
- 9.3Net effect on procedures
10Pricing and consignment3 sections
Realised price bands by device and country.
- 10.1Locking plates and nails
- 10.2Hip screws and external frames
- 10.3Consignment economics
11Regulation3 sections
Device clearance and certification.
- 11.121 CFR 888.3030 and 510(k)
- 11.2EU MDR and Regulation 2023/607
- 11.3Class II and Class III device routes
12Market size and forecast, 2025–20355 sections
Global value, volume and value per unit
- 12.1Market value, 2025–2035
- 12.2Volume (million procedures), 2025–2035
- 12.3Value per unit, 2025–2035
- 12.4Year-on-year growth
- 12.5Growth decomposition
13Orthopedic Trauma Implants market, by category16 sections
5 segments, value 2025–2035
- 13.1Overview and share, 2025 and 2035
- 13.2Plates and screws
- 13.2.1Market size and forecast, 2025–2035
- 13.2.2Growth outlook
- 13.3Intramedullary nails
- 13.3.1Market size and forecast, 2025–2035
- 13.3.2Growth outlook
- 13.4Hip fracture systems
- 13.4.1Market size and forecast, 2025–2035
- 13.4.2Growth outlook
- 13.5External fixators
- 13.5.1Market size and forecast, 2025–2035
- 13.5.2Growth outlook
- 13.6Bioabsorbable and other fixation
- 13.6.1Market size and forecast, 2025–2035
- 13.6.2Growth outlook
14Orthopedic Trauma Implants market, by fracture site16 sections
5 segments, value 2025–2035
- 14.1Overview and share, 2025 and 2035
- 14.2Hip and femur
- 14.2.1Market size and forecast, 2025–2035
- 14.2.2Growth outlook
- 14.3Wrist and forearm
- 14.3.1Market size and forecast, 2025–2035
- 14.3.2Growth outlook
- 14.4Ankle and tibia
- 14.4.1Market size and forecast, 2025–2035
- 14.4.2Growth outlook
- 14.5Shoulder and upper arm
- 14.5.1Market size and forecast, 2025–2035
- 14.5.2Growth outlook
- 14.6Pelvis and other sites
- 14.6.1Market size and forecast, 2025–2035
- 14.6.2Growth outlook
15Orthopedic Trauma Implants market, by material10 sections
3 segments, value 2025–2035
- 15.1Overview and share, 2025 and 2035
- 15.2Titanium
- 15.2.1Market size and forecast, 2025–2035
- 15.2.2Growth outlook
- 15.3Stainless steel
- 15.3.1Market size and forecast, 2025–2035
- 15.3.2Growth outlook
- 15.4Bioabsorbable polymers
- 15.4.1Market size and forecast, 2025–2035
- 15.4.2Growth outlook
16Orthopedic Trauma Implants market, by care setting7 sections
2 segments, value 2025–2035
- 16.1Overview and share, 2025 and 2035
- 16.2Hospitals
- 16.2.1Market size and forecast, 2025–2035
- 16.2.2Growth outlook
- 16.3Ambulatory surgery centers
- 16.3.1Market size and forecast, 2025–2035
- 16.3.2Growth outlook
17Regional analysis56 sections
5 regions with country tables
- 17.1Regional overview and share, 2025 and 2035
- 17.2North America
- 17.2.1Market size and forecast, 2025–2035
- 17.2.2By category
- 17.2.3By fracture site
- 17.2.4By material
- 17.2.5By care setting
- 17.2.6United States
- 17.2.7Canada
- 17.2.8Mexico
- 17.3Europe
- 17.3.1Market size and forecast, 2025–2035
- 17.3.2By category
- 17.3.3By fracture site
- 17.3.4By material
- 17.3.5By care setting
- 17.3.6Germany
- 17.3.7United Kingdom
- 17.3.8France
- 17.3.9Italy
- 17.3.10Spain
- 17.3.11Rest of Europe
- 17.4Asia Pacific
- 17.4.1Market size and forecast, 2025–2035
- 17.4.2By category
- 17.4.3By fracture site
- 17.4.4By material
- 17.4.5By care setting
- 17.4.6China
- 17.4.7Japan
- 17.4.8India
- 17.4.9South Korea
- 17.4.10Australia
- 17.4.11Southeast Asia
- 17.4.12Rest of Asia Pacific
- 17.5Latin America
- 17.5.1Market size and forecast, 2025–2035
- 17.5.2By category
- 17.5.3By fracture site
- 17.5.4By material
- 17.5.5By care setting
- 17.5.6Brazil
- 17.5.7Mexico
- 17.5.8Argentina
- 17.5.9Rest of Latin America
- 17.6Middle East and Africa
- 17.6.1Market size and forecast, 2025–2035
- 17.6.2By category
- 17.6.3By fracture site
- 17.6.4By material
- 17.6.5By care setting
- 17.6.6Saudi Arabia
- 17.6.7United Arab Emirates
- 17.6.8Turkey
- 17.6.9South Africa
- 17.6.10Rest of Middle East and Africa
18Competitive landscape15 sections
11 companies profiled
- 18.1Market concentration
- 18.2Market share analysis, 2025
- 18.3Strategic moves: acquisitions, launches, contracts
- 18.4Company profilesEach profile: overview, products, financials where reported, position in this market, recent developments
- 18.4.1J&J DePuy Synthes
- 18.4.2Stryker
- 18.4.3Zimmer Biomet
- 18.4.4Smith+Nephew
- 18.4.5Acumed
- 18.4.6Enovis
- 18.4.7Globus Medical
- 18.4.8Arthrex
- 18.4.9Weigao Orthopaedics
- 18.4.10Double Medical
- 18.4.11Johnson & Johnson
19Scenarios to 20355 sections
Slower, base and faster cases.
- 19.1Slower case
- 19.2Base case case
- 19.3Faster case
- 19.4Sensitivity of the 2035 value
- 19.5Published forecasts compared
20Douglas Exclusive: the fracture-site procedure atlas3 sections
Procedures and value by fracture site.
- 20.1Hip and femur
- 20.2Wrist and forearm, ankle and tibia
- 20.3Shoulder and upper arm, pelvis
21Appendix5 sections
Data, sources and licence
- 21.1Data tables (Excel model)
- 21.2Sources (12)
- 21.3Abbreviations
- 21.4Change log and next review
- 21.5Licence and how to cite
TList of tables51
- Table 1Market value, 2025–2035 (USD million)
- Table 2Volume, 2025–2035 (million procedures)
- Table 3Value per unit, 2025–2035
- Table 4Orthopedic Trauma Implants market by category, 2025–2035 (USD million)
- Table 5Plates and screws: market size, 2025–2035 (USD million)
- Table 6Intramedullary nails: market size, 2025–2035 (USD million)
- Table 7Hip fracture systems: market size, 2025–2035 (USD million)
- Table 8External fixators: market size, 2025–2035 (USD million)
- Table 9Bioabsorbable and other fixation: market size, 2025–2035 (USD million)
- Table 10Orthopedic Trauma Implants market by fracture site, 2025–2035 (USD million)
- Table 11Hip and femur: market size, 2025–2035 (USD million)
- Table 12Wrist and forearm: market size, 2025–2035 (USD million)
- Table 13Ankle and tibia: market size, 2025–2035 (USD million)
- Table 14Shoulder and upper arm: market size, 2025–2035 (USD million)
- Table 15Pelvis and other sites: market size, 2025–2035 (USD million)
- Table 16Orthopedic Trauma Implants market by material, 2025–2035 (USD million)
- Table 17Titanium: market size, 2025–2035 (USD million)
- Table 18Stainless steel: market size, 2025–2035 (USD million)
- Table 19Bioabsorbable polymers: market size, 2025–2035 (USD million)
- Table 20Orthopedic Trauma Implants market by care setting, 2025–2035 (USD million)
- Table 21Hospitals: market size, 2025–2035 (USD million)
- Table 22Ambulatory surgery centers: market size, 2025–2035 (USD million)
- Table 23Orthopedic Trauma Implants market by region, 2025–2035 (USD million)
- Table 24North America: market by category, 2025–2035 (USD million)
- Table 25North America: market by fracture site, 2025–2035 (USD million)
- Table 26North America: market by material, 2025–2035 (USD million)
- Table 27North America: market by care setting, 2025–2035 (USD million)
- Table 28North America: market by country, 2025–2035 (USD million)
- Table 29Europe: market by category, 2025–2035 (USD million)
- Table 30Europe: market by fracture site, 2025–2035 (USD million)
- Table 31Europe: market by material, 2025–2035 (USD million)
- Table 32Europe: market by care setting, 2025–2035 (USD million)
- Table 33Europe: market by country, 2025–2035 (USD million)
- Table 34Asia Pacific: market by category, 2025–2035 (USD million)
- Table 35Asia Pacific: market by fracture site, 2025–2035 (USD million)
- Table 36Asia Pacific: market by material, 2025–2035 (USD million)
- Table 37Asia Pacific: market by care setting, 2025–2035 (USD million)
- Table 38Asia Pacific: market by country, 2025–2035 (USD million)
- Table 39Latin America: market by category, 2025–2035 (USD million)
- Table 40Latin America: market by fracture site, 2025–2035 (USD million)
- Table 41Latin America: market by material, 2025–2035 (USD million)
- Table 42Latin America: market by care setting, 2025–2035 (USD million)
- Table 43Latin America: market by country, 2025–2035 (USD million)
- Table 44Middle East and Africa: market by category, 2025–2035 (USD million)
- Table 45Middle East and Africa: market by fracture site, 2025–2035 (USD million)
- Table 46Middle East and Africa: market by material, 2025–2035 (USD million)
- Table 47Middle East and Africa: market by care setting, 2025–2035 (USD million)
- Table 48Middle East and Africa: market by country, 2025–2035 (USD million)
- Table 49Company market shares, 2025
- Table 50Scenario values, 2035
- Table 51Sources and confidence grades by figure
FList of figures10
- Figure 1Market value, 2025–2035
- Figure 2Growth decomposition, 2026–2035
- Figure 3Share by category, 2025 and 2035
- Figure 4Share by fracture site, 2025 and 2035
- Figure 5Share by material, 2025 and 2035
- Figure 6Share by care setting, 2025 and 2035
- Figure 7Share by region, 2025 and 2035
- Figure 8Growth by region, 2026–2035
- Figure 9Market concentration, 2025
- Figure 10Scenario paths to 2035
Questions buyers ask
How many fixation procedures support orthopedic trauma implant revenue?
13.4 million in 2025, at USD 776 of implant spend each, which gives USD 10.40 billion. Douglas Insights expects 19.1 million procedures and USD 16.85 billion by 2035.
What share of the trauma implant market does DePuy Synthes hold?
About 30.3% of 2025 revenue, on Douglas Insights estimates anchored on J&J's fiscal 2025 trauma sales of USD 3.15 billion. With Stryker and Zimmer Biomet, the top three hold about 55.5%.
How much did China's procurement tenders cut trauma implant prices?
88.65% on average across 147 products in the Henan-led 12-province alliance. Locking plate systems fell from roughly 9,360 yuan to 987 yuan.
Why do bioabsorbable screws and pins grow faster than metal plates?
7.9% a year to 2035 against 4.6% for plates and screws, because resorbable polymer and magnesium implants avoid a second operation to remove hardware.
Which fracture site earns the most trauma implant revenue?
34.6% of value comes from hip and femur fixation, USD 3.60 billion, from 3.12 million procedures at USD 1,153 each, according to the Douglas Exclusive fracture-site procedure atlas.
Why is Asia Pacific the quickest-growing trauma implant region?
6.7% a year to 2035, as surgical fixation replaces casting across India and Southeast Asia, although Chinese tender pricing keeps revenue per case low.
What would change the 2035 trauma implant outlook most?
USD 13.85 billion to USD 19.69 billion is the 2035 range. One extra point of yearly procedure growth adds about USD 1.70 billion, and procurement spreading beyond China drives the slower case.
How are trauma implants regulated in the US and EU?
21 CFR 888.3030 makes most plates and screws Class II devices cleared by 510(k) in the US. EU legacy certificates for implantable Class IIb and Class III devices run to 31 December 2027.
Research & citation
This report was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.
Douglas Insights Inc (2026). Orthopedic Trauma Implants Market. Report DI-HC-10183, September 2026. https://www.douglasinsights.com/orthopedic-trauma-implants-market/